MS Patients Show Robust T-Cell Response to mRNA COVID-19 Vaccines
MS patients receiving anti-CD20 monoclonal antibody treatment can still mount T-cell responses
Multiple Sclerosis
FDA to Review sNDA for Purified Cortrophin Gel for Multiple Indications
Purified Cortrophin Gel is a purified adrenocorticotropic hormone.
New Drug Product: Ponvory
This slideshow show drug information for Ponvory. Click here for the complete Ponvory monograph.
Case Study: Herpes Zoster in Patients With MS Treated With Dimethyl Fumarate
This case study examines 2 patients with relapsing remitting multiple sclerosis, under dimethyl fumarate treatment, who developed severe herpes zoster infection.
High-Efficacy Therapy May Reduce Relapses in Active SPMS
But no difference in disability progression seen for high-efficacy versus low-efficacy therapy for secondary progressive multiple sclerosis
Certain ICD-10 Codes Often Precede Multiple Sclerosis Diagnosis
High proportion of these codes represent symptoms suggestive of demyelinating events or other neurologic diseases
FDA Rejects Aubagio sNDA for Pediatric Relapsing MS Indication
The labeling for Aubagio has been updated to include safety data from the pediatric clinical trial program.
FDA Denies Approval of Tysabri for Subcutaneous Administration
Currently, the FDA-approved route of administration of Tysabri for MS is through intravenous infusion.
AAN: Race May Affect Response to Anti-CD20 Therapy for MS, NMOSD
B-cell repopulation occurs more often in African American vs White patients between 6 and 12 months after anti-CD20 infusion
Ponvory Now Available for Relapsing Forms of Multiple Sclerosis
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator.
